RBC Capital Lowers Exelixis (EXEL) Price Target to $43 [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm's Sector Perform rating was maintained on the stock. In a research note, RBC Capital pointed out that after the reporting of the data from the HIF-2alpha inhibitors study by Exelixis, Inc. (NASDAQ:EXEL)'s competitor Merck (MRK), the share value of the company will potentially witness a decline in the range of 5% to 10%, owing to competitive pressures. Separately, H.C. Wainwright raised its price target on Exelixis, Inc. (NASDAQ:EXEL) from $52 to $54 while maintaining a Buy rating on February 12, 2026. Analysts updated their model following the reporting of the results for the fourth quarter of 2025. As of March 25, 2026, Exelixis, Inc. (NASDAQ:EXEL) maintains a Buy rating from 45% of 22 analysts followed by CNN, with a 1-year average upside potential of 15.47%. Founded in 1994, Exelixis, Inc. (NASDAQ:EXEL
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (EXEL) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- EXEL's page on the SEC website